Ain Holdings Inc. · TSE:9627
Ain — Ain Pharmaciez — FY4/13 Earnings Presentation
13 slides from Ain's earnings presentation, Jun 5, 2013
Slide 1: FY4/13 Results Briefing
FY4/13 Results Briefing June 5,2013
Slide 2: Results Overview
Results Overview © 2013 AIN PHARMACIEZ Inc. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L The Group reported net sales of ¥154,560 million, an increase of 8.2% year on year due to the opening of 83 stores including M&A. However, ordinary income declined 2.4% to ¥10,292 million, mainly reflecting the impact of upfront investment in the medical mall development business. F
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business（Consolidated） The dispensing pharmacy business reported net sales of ¥137,291 million, an increase of 8.0% year on year due to the opening of new dispensing pharmacies, as well as the impact of M&A, and segment income of ¥12,655 million, up 3.0%. FY4/12 FY4/13 FY4/13 YoY
Slide 5: Drug and Cosmetic Store Business (Consolidated)
Drug and Cosmetic Store Business(Consolidated) The drug and cosmetic store business reported net sales of ¥16,735 million, an increase of 8.7% year on year, and segment income of ¥14 million, down 88.6%. FY4/12 FY4/13 FY4/13 YoY YoY Vs plan (¥ million) results plan results change change(%) (%) Net s
Slide 6: Consolidated B/S
Consolidated B/S As a result of the opening stores and M&A, the total assets increased by ¥9,931 million to ¥95,839 million at the end of the previous fiscal year. Shareholders’ equity ratio improved 0.8 % to 40.0%, compared with 39.2% at the end of the previous fiscal year. (¥ million) (¥ million)
Slide 7: Assets
Assets Cash on hand and in banks increased by ¥2,525 million to ¥18,460 million year on year due to wider use of the securitization of dispensing fee receivables. Fixed assets increased by ¥7,106 million to ¥52,676 million year on year due to investment in new stores and expansion in the asset base
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets Net assets increased by ¥4,610 million to ¥38,356 million compared to ¥33,745 million at the end of the previous fiscal year. This was because the balance of retained earnings rose ¥4,278 million to ¥21,704 million due to the growth of retained earnings during the fiscal y
Slide 9: Consolidated C/F
Consolidated C/F The investment in business expansion is served enough by the business cash flows based on business profit. (¥ million) FY4/12 FY4/13 Change Income before income taxes and minority interests 9,782 9,694 (88) Depreciation and amortization 1,749 2,212 463 Amortization of goodwill 1,262
Slide 10: Business Value Analysis
Business Value Analysis End-FY4/11 End-FY4/12 End-FY4/13 Change Shareholders’ equity ratio (%) 38.3 39.2 40.0 0.8 Market value equity ratio (%) 64.5 79.6 79.3 (0.3) PER (times) 12.18 13.96 14.97 1.01 EPS (¥) 255.67 307.35 318.37 11.02 PBR (times) 1.68 2.03 1.98 (0.05) BPS (¥) 1,847.46 2,113.79 2,403
Slide 11: FY4/14 Plan (Consolidated)
FY4/13 Plan (Consolidated) Dispensing pharmacy business plans improvement of the profit by the opening of new dispensing pharmacies , M&A and the activation of same stores. Drug and cosmetic store business continues the store development of the urban drugstore. We forecast FY4/14 net sales will rise
Slide 12: AIN PHARMACIEZ INC. Corporate Planning Division
Inquiries related to this presentation should be addressed to AIN PHARMACIEZ INC. Corporate Planning Division TEL(81)11-783-5681 FAX(81)11-783-0224 E-MAIL: nozawa@ainj.co.jp http://www.ainj.co.jp/ This document may not be reproduced or distributed to any third party without prior approval of AIN PHA
Slide 13: AIN GROUP
AIN GROUP